BridgeMD
New treatment option for Prostate Cancer
Official title Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
ClinicalTrials.gov ID: NCT06807359
What this study is testing
What is Verteporfin Injection?
Verteporfin Injection is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for prostate cancer.
Also referred to as Visudyne.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- people ≥ 18 years.
- Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including people on active...
- Gleason Score 7 (3+4 or 4+3).
- PSA ≤ 15 ng/mL.
- Lesion volume on mpMRI \< 1.5 cm3.
You likely can't join if
- Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease.
- Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI
- Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy)
- High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as \>1 core of GG1 with a linear amount...
- Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.
- Prior treatment with any form of brachytherapy.
See the full eligibility criteria
- people ≥ 18 years.
- Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including people on active surveillance with evidence of disease progression and a prostate biopsy not...
- Gleason Score 7 (3+4 or 4+3).
- PSA ≤ 15 ng/mL.
- Lesion volume on mpMRI \< 1.5 cm3.
- Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer. \- Bone scan is optional if PSA \< 10 ng/mL.
- Treatment target volume \<50 cm3 defined by TRUS or MRI.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Expected survival ≥ 36 months.
- Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.
- Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.
- Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.
- Signed Informed Consent.
- Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease.
- Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI
- Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy)
- High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as \>1 core of GG1 with a linear amount of carcinoma \>6mm.
- Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.
- Prior treatment with any form of brachytherapy.
- Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer.
- Prior or current bleeding diathesis.
- Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site.
- Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment.
- Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from...
- Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator.
- Contraindication for photosensitizer including:
- Porphyria or other diseases exacerbated by light.
- Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients.
- Known allergies to porphyrins.
- On-going therapy with a photosensitizing agent.
- Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study.
- Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment (glomerular filtration rate [GFR] \<30 mL/min/1.73m2), or previous contrast reactions.
- Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
- Cologne, Germany
- Rostock, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States; Cologne, Germany; Rostock, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.